Skip to main content
. Author manuscript; available in PMC: 2022 Dec 9.
Published in final edited form as: Cell. 2021 Nov 30;184(25):6101–6118.e13. doi: 10.1016/j.cell.2021.11.007

Figure 1. GC B cells and TFH cells correlate with favorable clinical outcomes in LUAD patients.

Figure 1.

A, Estimated fractions of immune cell subsets from bulk expression data of primary tumor tissues in TCGA-LUAD patient cohort (n=513). CIBERSORT algorithm was used for deconvolution.

B – E, scRNA-seq analyses (GSE131907, Kim et.al.) of T/NK and B cell clusters in treatment-naïve human LUAD samples from primary sites (tLung), metastatic LNs (mLN), normal lung tissues (nLung) and normal LNs (nLN). B – C, UMAP displaying T/NK (B) and B cell clusters (C). D – E, Bar graphs displaying tissue origins (top) and heatmaps (bottom) showing relative abundance of signature genes in CD4 T cell (D) and B cell clusters (E).

F – G, Survival analyses based on GC B cell-signature (F) and TFH-signature (G) in TCGA-LUAD patient cohort (n=478).

H, Correlation analyses on GC B cell-signature and TFH-signature in TCGA-LUAD cohort.

I, Heatmap showing R values for the correlations among expression signatures of GC B cells, TFH, Th1, CD8 effector cells, Th17, NK cells in TCGA-LUAD cohort.

F – G, log-rank Mantel-Cox test. H – I, two-tailed Pearson correlation test.